Christie, Kathleen A.
Guo, Jimmy A.
Silverstein, Rachel A.
Doll, Roman M. http://orcid.org/0000-0003-3991-6043
Mabuchi, Megumu
Stutzman, Hannah E.
Lin, Jiecong
Ma, Linyuan
Walton, Russell T. http://orcid.org/0000-0002-0546-474X
Pinello, Luca http://orcid.org/0000-0003-1109-3823
Robb, G. Brett http://orcid.org/0000-0002-2382-2256
Kleinstiver, Benjamin P. http://orcid.org/0000-0002-5469-0655
Funding for this research was provided by:
Massachusetts General Hospital (Fund for Medical Discovery (FMD) Fundamental Research Fellowship Award, MGH Executive Committee on Research Howard M. Goodman Fellowship)
National Science Foundation (Graduate Research Fellowship Program under Grant No. 1745302)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R35 HG010717)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (P01 HL142494)
Article History
Received: 17 November 2021
Accepted: 31 August 2022
First Online: 6 October 2022
Competing interests
: K.A.C., R.T.W. and B.P.K are inventors on patents and/or patent applications filed by Mass General Brigham that describe genome engineering technologies, including for the development of SpRY (R.T.W. and B.P.K.). B.P.K. is a consultant for EcoR1 Capital and is an advisor to Acrigen Biosciences, Life Edit Therapeutics and Prime Medicine. L.P. has financial interests in Edilytics and SeQure Dx, Inc. L.P.ʼs interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. M.M. and G.B.R. are employees of the Research Department at New England Biolabs (NEB). NEB is a commercial supplier of molecular biology reagents, including some that were used in this work. The remaining authors declare no competing interests.